ZIMMER BIOMET HOLDINGS, INC.
Close on Oct 19, 2026
- Market cap
- $18.31B
- P/E (TTM)
- 23.1
- Dividend yield
- 1.01%
About Zimmer Biomet
Orthopedic, Prosthetic & Surgical Appliances & Supplies, SIC 3842
The provided excerpt consists solely of raw XBRL taxonomy tags, accounting data, and SEC filing metadata without explanatory narrative detailing the entity's core operations or commercial activities. Inferred from product line and segment identifiers, the company operates in medical products and devices, featuring offerings and operating segments associated with knees, hips, surgical equipment, bone cement, and healthcare data technology. The provided text contains no details or statements identifying its end users or customers.
Regarding operational scale and physical presence, the text includes no disclosures concerning facility counts, store counts, employee figures, or headquarters location. Geographic scope is noted purely through regional segment designations and country references, specifically including the Americas, EMEA, Asia Pacific, the United States, and China, in addition to mentions of Swiss and European debt obligations.
Summary of the business section of Zimmer Biomet's latest annual report, written by StockData.
Company profile
Company
- Legal name
- ZIMMER BIOMET HOLDINGS, INC.
- Founded
- 1927
- Headquarters
- Warsaw, IN
- Address
- 345 East Main Street 46580
- Phone
- (574) 267-6131
- Website
- zimmerbiomet.com
- Employees
- 17,000, Dec 31, 2025
- Industry
- Orthopedic, Prosthetic & Surgical Appliances & Supplies
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- PricewaterhouseCoopers LLP, Chicago, Illinois
Stock & identifiers
- Ticker
- ZBH
- Exchange
- NYSE
- IPO date
- Jul 25, 2001
- Shares outstanding
- 191M, Jul 30, 2026
- Public float
- $18.02B, Jun 30, 2025
- Filer category
- Large accelerated filer
- SEC CIK
- 1136869
- CUSIP
- 98956P102
- ISIN
- US98956P1021
- LEI
- 2P2YLDVPES3BXQ1FRB91
- EIN
- 13-4151777
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Ivan Tornos | Chairman, President and CEO, Director | 83,432 |
| Kevin R. Thornal | Grp Pres-Global Business | 0 |
| Chad F. Phipps | See remarks below. | 65,231 |
| Chintan Desai | President, APAC | – |
| Jehanzeb Noor | See remarks below. | 5,151 |
| Sang Yi | Group President, Asia Pacific | 27,251 |
| Paul A. Stellato | VP, Controller, CAO | 5,257 |
| Lori Winkler | SVP and CHRO | 10,224 |
| Suketu Upadhyay | Exec VP, CFO | 69,485 |
| Zuilen Wilfred Van | Group Pres, EMEA | 30,652 |
| Mark Bezjak | President, Americas | 13,772 |
| Rachel Ellingson | Chief Administrative Officer | 11,906 |
| Maria Teresa Hilado | Director | 1,650 |
| Devdatt Kurdikar | Director | – |
| Louis Shapiro | Director | – |
| Michael J. Farrell | Director | 2,000 |
| Sreelakshmi Kolli | Director | 1,000 |
| Robert Hagemann | Director | 4,000 |
| Arthur J. Higgins | Director | 2,900 |
| Syed A. Jafry | Director | 4,060 |
| Betsy J. Bernard | Director | 5,271 |
| Christopher B. Begley | Director | 3,540 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 Mr Tornos | $16.11M | $12.57M | $6.11M | $63 | $127 |
| FY2024 Mr Tornos | $14.99M | $9.24M | $3.89M | $73 | $117 |
| FY2023 Mr Hanson | $12.76M | -$19.16M | $5.02M | $83 | $106 |
| FY2023 Mr Tornos | $10.19M | $10.29M | $5.02M | $83 | $106 |
| FY2022 Mr Hanson | $16.45M | $20.50M | $4.69M | $87 | $97 |
| FY2022 Mr Tornos | $0 | $0 | $4.69M | $87 | $97 |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we employed approximately 17,000 employees worldwide, including approximately 2,000 employees dedicated to research and development.”
Corporate history
Events identified from SEC filings